Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 3Salivary Gland Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3trastuzumab deruxtecan 2Cisplatin 2Biopsy 2pembrolizumab 1luprolide acetate gel depot 1entrectinib 1dehydroftorafur 1darolutamide 1ceralasertib 1apalutamide 1amivantamab 1Surveys and Questionnaires 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Platinum 1Pemetrexed 1Leuprolide 1Immunoglobulin G 1Gonadotropin-Releasing Hormone 1Glutamate Carboxypeptidase II 1Fluorouracil 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × Glutamate Carboxypeptidase II × 30 days × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡